Medinet Co., Ltd. (2370) on Oct. 16 lowered its sales forecast for the fiscal year ended Sept. 30, 2026, by 12.9% to ¥821 million from ¥943 million, widening its projected operating loss to ¥1,520 million while narrowing its expected net loss to ¥1,426 million.
The Tokyo Stock Exchange Growth-listed regenerative medicine company had issued the previous forecast on Nov. 13, 2025. The operating loss is now seen ¥66 million larger than previously forecast, while the ordinary loss is expected at ¥1,360 million, ¥89 million smaller, and the net loss ¥27 million smaller. Net loss per share is projected at ¥5.19, versus ¥5.49 previously.
| Item (¥ million) | Previous | Revised | Change | FY2025 actual |
|---|---|---|---|---|
| Sales | 943 | 821 | -121 | 810 |
| Operating profit | -1,454 | -1,520 | -66 | -1,445 |
| Ordinary profit | -1,449 | -1,360 | +89 | -1,339 |
| Net profit | -1,453 | -1,426 | +27 | -1,362 |
| EPS (¥) | -5.49 | -5.19 | +0.30 | -5.15 |
In its specified cell-processed products business, the number of S-DSC® processing cases, based on technology provided by Shiseido, exceeded the prior year. However, immune-cell sales fell as some partner medical institutions saw fewer overseas patients from a country that had temporarily restricted travel to Japan, and the launch of new offerings including adipose-derived mesenchymal stromal cells (ASC) was delayed, generating no sales. In the CDMO business, Medinet completed and booked sales from a technology transfer toward contract manufacturing of investigational products for T-Cell Nouveau Co., Ltd., but several contract projects slated to begin manufacturing during the year slipped into the fiscal year ending September 2027.
Lower general administrative expenses were offset by the sales shortfall and higher R&D spending, as development advanced after the company exercised an option for exclusive development and commercialization rights to Stempeucel® (development code MDNT-03), an allogeneic mesenchymal stromal cell product approved for manufacturing and marketing in India. Ordinary results improved on strong investment partnership performance and a reversal of allowance for doubtful accounts following partial recovery of long-term loans.
| Hikari Tsushin, Inc. | |
| Offer price | ¥1,000 per common share |
| M&A / TOB | 1 |
| Guidance | 0 |
| Buybacks | 0 |
| Dividends | 0 |
| Capital | 0 |
| Earnings | 0 |
| People | 0 |
Summaries of public disclosures by Japanese listed companies. Not investment advice; accuracy not guaranteed. Figures and dates in the TDnet originals prevail.
本站內容為日本上市公司公開開示之摘要整理,非投資建議,亦不保證正確。數字與日程以 TDnet 原文為準。
本サイトは日本の上場企業の適時開示を要約したものであり、投資助言ではありません。正確性は保証しません。数値・日程は TDnet の原文が優先します。